Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 6/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PRKX | P51817 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023679 | 0.85 | SLC34A1 (0.43) | PTGS2GRM5HTR6HSD17B10 | |
| SCHEMBL23013548 | 0.85 | DHODH (0.41) | PTGS2DHODHHTR6ADORA2ADHFR | |
| SCHEMBL29703800 | 0.85 | DHODH (0.41) | PTGS2DHODHHTR6ADORA2ADHFR | |
| SCHEMBL23023590 | 0.82 | PTGS2 (0.44) | PTGS2GRM5HTR6ADORA2APDE4B | |
| SCHEMBL29939646 | 0.80 | KMO (0.42) | PTGS2DHODHHTR6KMOPDE4B | |
| SCHEMBL25150405 | 0.78 | PTGS2 (0.41) | PTGS2GRM5HTR6ADORA2APDE4B | |
| SCHEMBL15307034 | 0.74 | HTR6 (0.40) | PTGS2HTR6ADORA2AHSD17B10 | |
| SCHEMBL29692128 | 0.73 | CCKBR (0.56) | — | |
| SCHEMBL18208948 | 0.73 | POLB (0.42) | PTGS2HTR6 | |
| SCHEMBL29703797 | 0.71 | ALDH1A1 (0.44) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | PTGS2 3935/4885DHODH 3532/4885GRM5 312/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | PTGS2 3812/4885DHODH 3256/4885GRM5 464/4885 |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | CHRNA6, GABRA6, CHRNA7 | PTGS2 3935/4885DHODH 3532/4885GRM5 312/4885 |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | GABRA6, CNR1, CHRNA6 | PTGS2 3897/4885DHODH 3350/4885GRM5 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.